国产精品av在线观看不_日韩久久美女毛片_黄色网站在线性爱视频_9691精品人妻无码久久久_成年AV免费网址大全超清_亚洲aⅴ天堂无码_曰本裸色私人影院噜噜噜影院_另类视频无码视频国产精品_网红三级在线播放_美腿丝袜在线观看

Entries by

TOTAL SYNTHESIS AND NONCLINICAL STUDY RESULTS OF A NOVEL ANTICANCER DRUG CANDIDATE E7130 DERIVED FROM TOTAL SYNTHESIS OF HALICHONDRIN FOUND IN JOINT RESEARCH BETWEEN EISAI AND HARVARD UNIVERSITY SCIENTISTS, PUBLISHED IN SCIENTIFIC REPORTS

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that a joint research group including scientists from Eisai and Professor Yoshito Kishi’s group of Harvard University has achieved a total synthesis and obtained results of nonclinical studies of the novel compound, E7130, derived from total synthesis of halichondrin. These results have been published in?Scientific Reports, a scientific journal of?Nature.1?Currently a Phase I study to investigate E7130 in solid tumor is underway in Japan.

2019/6/17 by

EISAI TO PRESENT LATEST DATA ON LEMBOREXANT INCLUDING INTEGRATED ANALYSIS OF PHASE III CLINICAL STUDIES AT 33RD ANNUAL SLEEP MEETING

Eisai Co.,Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) today announced that latest information on lemborexant, an investigational sleep-wake regulation agent being studied for the treatment of multiple sleep-wake disorders, including insomnia and Irregular Sleep-Wake Rhythm Disorder (ISWRD) will be presented at the 33rd Annual Meeting of the Associated Professional Sleep Societies (SLEEP 2019), from June 8 to 12 in San Antonio, Texas, the United States.

2019/5/29 by

EISAI TO PRESENT DATA ON ONCOLOGY PIPELINE AND PRODUCTS AT 55TH ASCO ANNUAL MEETING

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that presentations on a series of abstracts highlighting updates regarding its in-house discovered lenvatinib mesylate (product name: Lenvima?, “lenvatinib”, kinase inhibitor), eribulin mesylate (product name: Halaven?, “eribulin”, halichondrin class microtubule dynamics inhibitor), and MORAb-202 (antibody drug conjugate, ADC) will be given at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, the United States, from May 31 to June 4, 2019. The latest information on H3B-6527 (fibroblast growth factor receptor 4 inhibitor) and H3B-6545 (selective estrogen receptor?α covalent antagonist), which were discovered by Eisai’s U.S. oncology precision medicine-focused research and development subsidiary H3 Biomedicine Inc., will also be highlighted in presentations at ASCO.

2019/5/16 by

EISAI BUYS OUT PURDUE RIGHTS TO END COLLABORATION

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announces today that its U.S. subsidiary Eisai Inc. has bought out Purdue Pharma L.P.’s rights in the worldwide collaboration for the development and commercialization of lemborexant, an investigational sleep-wake regulation agent being studied for the treatment of multiple sleep-wake disorders, including insomnia and irregular sleep-wake rhythm disorder (ISWRD) in patients with Alzheimer’s Disease. Eisai group will solely conduct the development and the commercialization of lemborexant globally.

2019/5/1 by

EISAI TO PRESENT LATEST DATA ON LEMBOREXANT AND PERAMPANEL AT ANNUAL AMERICAN ACADEMY OF NEUROLOGY MEETING

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the latest data on its dual orexin receptor antagonist lemborexant and its antiepileptic drug (AED) perampanel (product name: Fycompa?) will be presented at the 2019 Annual American Academy of Neurology (AAN) Meeting to be held from May 4 to 10, 2019 in Philadelphia, Pennsylvania in the United States.

2019/4/24 by

DATA SAFETY MONITORING BOARD RECOMMENDS CONTINUATION OF PHASE III CLINICAL STUDIES OF BACE INHIBITOR ELENBECESTAT IN EARLY ALZHEIMER’S DISEASE

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that in the 8th meeting of the Data Safety Monitoring Board (DSMB) for the global Phase III clinical studies (MISSION AD) on the investigational oral BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat (development code: E2609) in early Alzheimer’s disease (AD), the DSMB reviewed safety data including the potential for decline in cognition, and recommended the continuation of the studies. Elenbecestat is being jointly developed by Eisai and Biogen Inc. (Headquarters: Cambridge, Massachusetts, United States).

2019/3/29 by

INITIATION OF PHASE III CLINICAL TRIAL OF BAN2401 IN EARLY ALZHEIMER’S DISEASE

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced that a global Phase III clinical study (Clarity AD/Study 301) of BAN2401, an anti-amyloid beta protofibril antibody, in patients with early Alzheimer’s disease has been initiated. BAN2401 is being jointly developed by Eisai and Biogen Inc. (Headquarters: Cambridge, Massachusetts, United States, “Biogen”).

2019/3/22 by

Eisai and Imbrium Therapeutics Announce U.S. FDA Filing Acceptance of New Drug Application for Lemborexant for the Treatment of Insomnia

TOKYO and STAMFORD, Conn. – March 12, 2019 – Eisai Co., Ltd. (CEO: Haruo Naito, “Eisai”) and Imbrium Therapeutics L.P. (Imbrium Therapeutics), a clinical-stage biopharmaceutical company and operating subsidiary of Purdue Pharma, L.P. (President and CEO: Craig Landau, MD) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for lemborexant, an investigational agent being studied for the treatment of insomnia, a sleep-wake disorder. A Prescription Drug User Fee Act (PDUFA) date is set for December 27, 2019.

2019/3/12 by